Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605782 · ClinicalTrials.gov registry record
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
A clinical trial of Multiple Sclerosis (Relapsing Remitting), sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 9,000
- Enrollment target
- 1
- Study location
NCT05605782: Active study of Multiple Sclerosis (Relapsing Remitting), sponsored by Bristol-Myers Squibb.
NCT05605782 is a study of Multiple Sclerosis (Relapsing Remitting) that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 9,000 participants, above the 252-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (3471% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05605782, a study of Multiple Sclerosis (Relapsing Remitting), is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 9,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two population of participants: * Participants not exposed to ozanimod with RRMS who have received treatment with other S1P-receptor modulators disease modifying treatments (DMTs) * Participants not exposed to ozanimod with RRMS who have received treatment with other non-S1P-receptor modulators disease modifying treatments (DMTs)
Conditions Studied
Study Locations (1)
Maryland
- Evidera - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,000 participants |
| Start Date | 2021-09-02 |
| Est. Completion | 2033-07-26 |
What the registry record for NCT05605782 still lists
NCT05605782 is an observational study that tracks outcomes without assigning an intervention. Its 9,000 participants enrollment target places it among the larger protocols in the corpus, above the 252-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (3471% higher).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 0 interventions.
NCT05605782 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05605782 about?
NCT05605782 is a clinical study titled "A Post-Authorization, Long-term Study of Ozanimod Real-world Safety". The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two po...
What is the current status of trial NCT05605782?
This trial is currently active not recruiting. The enrollment target is 9,000 participants. The study started on 2021-09-02. Estimated completion is 2033-07-26.
What conditions does trial NCT05605782 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
Who is sponsoring clinical trial NCT05605782?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05605782 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05605782's enrollment target sits among peer trials
9,000 1st of 29 higher than 29 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
MS-ResearchBiomarkerS
RECRUITING
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI